Inhibition of placental growth factor in renal cell carcinoma
- PMID: 25550599
Inhibition of placental growth factor in renal cell carcinoma
Abstract
Background/aim: Placental growth factor (PlGF) is up-regulated in major malignant diseases or following antiangiogenic therapy, although it is present in low levels under normal physiological conditions. TB403, a monoclonal antibody against PlGF, was investigated in clear cell renal cell carcinoma (ccRCC) xenografts since it has been proposed as a potential target in oncology.
Materials and methods: Human ccRCCs were implanted in athymic nude mice to evaluate the efficacy of TB403 and to excise xenograft tumors for molecular experiments.
Results: TB403 did not significantly inhibit tumor growth in treatment-naïve or sunitinib-resistant ccRCC xenografts. Gene expression profiling resulted in over-expression of the C1orf38 gene, which induced immunoreactivity in macrophages. Angiogenesis PCR arrays showed that VEGFR-1 was not expressed in ccRCC xenografts.
Conclusion: PlGF blockade did not have a broad antiangiogenic efficacy; however, it might be effective on-target in VEGFR1-expressing tumors. The inhibition of VEGF pathway may induce the activity of tumor-associated-macrophages for angiogenesis escape.
Keywords: Placental growth factor (PlGF); antiangiogenic therapy; renal cell carcinoma; sunitinib resistance.
Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Similar articles
-
Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.Cancer Res. 2010 Feb 1;70(3):1053-62. doi: 10.1158/0008-5472.CAN-09-3722. Epub 2010 Jan 26. Cancer Res. 2010. PMID: 20103629
-
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.J Clin Oncol. 2008 Aug 1;26(22):3743-8. doi: 10.1200/JCO.2007.15.5416. J Clin Oncol. 2008. PMID: 18669461 Clinical Trial.
-
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.Cancer Res. 2017 Dec 1;77(23):6651-6666. doi: 10.1158/0008-5472.CAN-17-0899. Epub 2017 Oct 4. Cancer Res. 2017. PMID: 28978636 Free PMC article.
-
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.Clin Cancer Res. 2007 Feb 15;13(4):1098-106. doi: 10.1158/1078-0432.CCR-06-1989. Clin Cancer Res. 2007. PMID: 17317817 Review.
-
[The role of angiogenesis in renal carcinoma].G Ital Nefrol. 2008 May-Jun;25(3):297-305. G Ital Nefrol. 2008. PMID: 18473301 Review. Italian.
Cited by
-
[Therapeutic mechanism of natural astaxanthin against renal clear cell carcinoma based on network pharmacology and bioinformatics].Nan Fang Yi Ke Da Xue Xue Bao. 2021 Dec 20;41(12):1763-1772. doi: 10.12122/j.issn.1673-4254.2021.12.02. Nan Fang Yi Ke Da Xue Xue Bao. 2021. PMID: 35012906 Free PMC article. Chinese.
-
Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models.Int J Mol Sci. 2020 Feb 18;21(4):1388. doi: 10.3390/ijms21041388. Int J Mol Sci. 2020. PMID: 32085654 Free PMC article. Review.
-
Long non-coding RNA ARAP1-AS1 contributes to cell proliferation and migration in clear cell renal cell carcinoma via the miR-361-3p/placental growth factor axis.Bioengineered. 2021 Dec;12(1):6629-6642. doi: 10.1080/21655979.2021.1975019. Bioengineered. 2021. PMID: 34516333 Free PMC article.
-
Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma.Oncotarget. 2018 May 1;9(33):23003-23017. doi: 10.18632/oncotarget.25190. eCollection 2018 May 1. Oncotarget. 2018. PMID: 29796168 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
